Early Access to IsoPlexis' Single Cell Analytics Platform Enhances Cell Therapy Program at World-renowned Research and Treatment Center. IsoPlexis, the leading developer of single-cell analytics solutions which enables complete immune cell profiling, has placed its ground-breaking IsoLight platform at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases. IsoPlexis provides early access to its innovative platform to leading biopharmaceutical companies, researchers, and trial centers to generate proof of concept data and to solve immediate challenges in the fast moving immune-oncology field and beyond.
IsoPlexis Announces Expansion into Asia Pacific. IsoPlexis announced today an exclusive agreement with Tekon Biotech, a leading instrumentation distributor, to distribute IsoPlexis' products in China. Tekon Biotech's first conference featuring IsoPlexis's systems will be held at Purple Mountain Hotel, Pudong, on September 20th, 2018 in Shanghai. "We are very excited to partner with Tekon Biotech, a world class distributor of life science systems and technology in China," said IsoPlexis Chief Executive Officer, Sean Mackay. "We see significant demand for our unique single-cell platform from leading Chinese pharmaceutical companies, research laboratories, and academic institutions. We are confident this partnership will help accelerate research in the fast emerging CAR-T therapy area in China, as we continue to extend our single-cell leadership into new markets."
IsoPlexis Places IsoLight Single-Cell Proteomic Detection Instrument at Fred Hutchinson Cancer Research Center. The sample-to-answer IsoLight benchtop system analyzes IsoPlexis' IsoCode chip to provide clinical and translational researchers a powerful, yet straightforward solution for establishing immune response functional correlates with outcome in key therapeutic areas like CAR-T and other cellular immunotherapies. The IsoCode Chip was recognized as The Scientist's and Fierce Life Science's #1 innovation of 2017 for its ability to provide both single-cell sensitivity and highly multiplexed and quantitative functional ELISA detection together for the first time.
IsoPlexis Announces Research Collaboration with Nektar Therapeutics. The collaboration is focused on further defining the functional impact of NKTR-214 in the clinic, at the single-cell level, with the goal of revealing both mechanism and potential immune correlates with outcome. Recently, preclinical data captured by IsoPlexis' IsoCode Chip in a study led by UCLA (AACR 2018) provided evidence that Nektar's cytokine agonist NKTR-214 can significantly boost the activation of critical T cell subsets, termed polyfunctional T cells, in combination with adoptive cell transfer (ACT) therapies.
Clinical Data Highlighting Single-Cell Polyfunctionality as a Potential Predictor of Patient Response to CAR-T Cell Therapy Published in Blood. The clinical data demonstrates a significant association between the functionality of anti-CD19 CAR-T cell product before treatment, as defined by IsoPlexis' Polyfunctional Strength Index (PSI), and the objective response in patients with non-Hodgkin lymphoma. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy before treatment, as well as to improve both pre-infusion product potency testing and guide cell product optimization. These findings have been published in Blood and are the result of a collaboration between IsoPlexis and Kite, a Gilead Company. Researchers used the IsoCode, IsoPlexis' single-cell precision engineering platform, to analyze CAR-T cell therapy products from 20 patients with non-Hodgkin lymphoma. Using IsoCode, researchers captured data to determine the PSI of each product. This PSI metric was associated with complete or partial patient response to the anti-CD19 CAR-T cell product. Other pre-infusion metrics tested in this study were not predictive.
IsoPlexis Recognized with the Pharma Tech Outlook Cover Story as Top 10 Analytics Solution Provider in 2018. The award focuses on IsoPlexis' IsoSpeak software suite's ability to clarify results, reports, and associations from large, complex patient data sets, thereby delivering leading biopharma and clinical researchers better data by which to determine effective cancer immunotherapies.
IsoPlexis' New IsoLight Instrument Receives the Red Dot Design Award for Highest Design Quality. The IsoLight sample-to-answer instrument receives the Red Dot Design Award for high design quality and focus on the user experience within the life sciences instrumentation category. The IsoLight's integrated design combines precision imaging and fluidics with a user-friendly software interface to create a uniquely easy to use single-cell system.
UCLA and Caltech Study Uses Technology Being Commercialized by IsoPlexis To Characterize Cancer Cells Resistant to Targeted Treatments. Research using novel single-cell detection technology being commercialized by IsoPlexis, called the Iso-Omix Chip, was highlighted in the Proceedings of the National Academy of Sciences. "Our single-cell proteomics technology allowed us to profile signaling pathways in melanoma cells that were both suppressed and activated via drugging. This, in turn, revealed how the cancer cells adapted and developed resistance to targeted treatments," said Dr. James Heath, a co-author of the UCLA paper and the Elizabeth W. Gilloon Professor of Chemistry at Caltech.
IsoPlexis Wins 2017 Fierce Technology Innovation Award. IsoPlexis’ IsoCode Chip and IsoLight Platform recognized by publishers of FierceBiotech and FiercePharma as this year’s top technology innovation in the life sciences space. "It is an honor to receive this award from the publishers of FierceBiotech and FiercePharma," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "Clinical researchers at leading academic and biopharmaceutical labs are using IsoPlexis technology to better understand how to use the human immune system in the fight against cancer, and we're proud that our technology is helping to advance more personalized and more potent immunotherapies for patients that need them the most."
The Scientist Names IsoPlexis Technology The Top Innovation of 2017. IsoPlexis’ single-cell technology recognized as a detection system poised to revolutionize clinical research and advance scientific knowledge. "Being named The Scientist’s No. 1 innovation of 2017 is another validation of the IsoPlexis technology’s role in utilizing our immune system to fight cancer," said Rong Fan, Ph.D., IsoPlexis Co-Founder and Scientific Advisory Board Chair, and an Associate Professor of Biomedical Engineering at Yale University. "IsoPlexis’ technology is helping researchers capture and understand large quantities of highly precise data, which will lead to more potent immunotherapies for more patients."
Journal for ImmunoTherapy of Cancer Highlights New Single Cell Bioinformatics Tools From IsoPlexis Used To Characterize Differences in CAR-T Products. IsoCode, IsoPlexis' single-cell precision platform, captured novel data from CAR-T products developed by Novartis Pharmaceuticals (Novartis), leading to IsoPlexis' development of new bioinformatics tools for visualizing high-dimensional, single-cell, proteomics data. Researchers from IsoPlexis and Novartis published the results from their collaboration in the November issue of the Journal for ImmunoTherapy of Cancer.
IsoPlexis Receives $5.6 Million in NIH Funding To Develop Next-Generation Single-Cell Assay Products, Technologies and Applications. “We’re excited to use this NIH grant support to advance our research and development in areas of solid tumor immunotherapies, bone marrow disease, autoimmune diseases and infectious diseases,” said Sean Mackay, IsoPlexis CEO and Co-Founder. “By expanding the application of our single-cell detection technologies, we aim to enable clinical researchers to better target their personalized treatments, at the single-cell level, and improve outcomes for high-need patients.”
IsoPlexis Receives $1.8M National Cancer Institute Grant To Develop Automated Platform To Assess CAR-T Product Potency and Toxicity and Predict Patient Response. "This new grant demonstrates the commitment to advancing CAR-T through investments, not only in the area of therapeutic discovery, but also in next-generation engineering technology," said Sean Mackay, IsoPlexis Chief Executive Officer and Co-Founder. "We're excited to be in a position to further enable this fast-growing field to better characterize and understand these complex therapies, and improve treatments for high-need patients."
IsoPlexis Raises $13.5 Million in Series B Financing. The Series B financing round was led by Spring Mountain Capital, with participation by Connecticut Innovations, North Sound Ventures, and Ironwood Capital. "IsoPlexis' collaboration data and product development has continued to demonstrate both the need for the IsoPlexis technology and the potential to have a large impact on improving patient outcomes," said Gregory P. Ho, President of Spring Mountain Capital and IsoPlexis Board Director. "We are excited to continue our partnership with the IsoPlexis team to move the company forward."
IsoPlexis and Kite Pharma Report Clinical Biomarker Data at AACR. IsoPlexis collaboration offers breakthrough insights into detecting and predicting patient response to t-cell therapy. Data captured by IsoCode, IsoPlexis' single-cell precision engineering platform, detected a statistically significant association between the potency of CAR-T cell product prior to treatment and objective response of cancer patients post-treatment. The results highlight the potential to predict whether cancer patients will respond to CAR-T cell therapy prior to treatment, as well as to improve both pre-infusion potency testing and cell product design.
IsoPlexis Obtains Exclusive License to Breakthrough Single-Cell Metabolomics Analysis Technologies From Dr. James Heath’s Lab at Caltech. Dr. James Heath’s new inventions enable detection of multiple types of metabolite information from single cells, a capability that aligns well with the IsoCode technology, previously referred to as the SCBC (single-cell barcode chip) solution and the foundation of IsoPlexis’ technologies.
IsoPlexis Adds Infectious Disease Pioneer Dr. David Ho to its Scientific Advisory Board. Dr. Ho is a recognized pioneer in the infectious disease area. He has authored more than 400 publications, was named Time magazine's 1996 Man of the Year for his pioneering work in AIDS research and is the recipient of 12 honorary doctorates for his scientific contributions.
IsoPlexis Awarded NIH SBIR Grant to Develop Single-Cell Analysis Platform to Facilitate Cancer Immunotherapy. IsoPlexis was recently awarded a competitive Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute of the National Institutes of Health to develop a multi-protein, single-cell analysis platform to facilitate personalized cancer immunotherapy response detection.
IsoPlexis Awarded NIH SBIR Grant to Develop Cellular Analysis Platform to Diagnose and Monitor Alzheimer's. IsoPlexis was recently awarded a competitive Phase I Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health to develop a system to analyze trafficking leukocytes' highly multiplexed proteomic responses in patients with Alzheimer's disease.
IsoPlexis Appoints Academic and Industry Experts to Inaugural Scientific Advisory Board. IsoPlexis today announced the formation of a scientific advisory board (SAB) to help guide the company’s strategic direction in novel areas of immunology and oncology.